Online inquiry

IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11634MR)

This product GTTS-WQ11634MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets LAG3&PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002286.6; NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902; 5133
UniProt ID P18627; Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11634MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12997MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ6415MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ210MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 13C5.5
GTTS-WQ14094MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-421
GTTS-WQ3261MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ART621
GTTS-WQ14156MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ6107MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA COR-001
GTTS-WQ8055MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA h2H12ec
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW